| Filed On | Filing |
|---|---|
| 19 Oct 2026 | DEFA14A |
| 19 Oct 2026 | DEFA14A |
| 19 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
THIS TRANSACTION AGREEMENT (this “Agreement”), dated as of October 18, 2026, is by and between MERCK KGAA, DARMSTADT, GERMANY, a German corporation with general partners (“Purchaser”), and SILENCE THERAPEUTICS PLC, a public limited compa... |
| 13 Oct 2026 | SCHEDULE 13G/A |
| 13 Oct 2026 | SCHEDULE 13G |
| 13 Aug 2026 | SCHEDULE 13D/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 |
Form 4: Griffiths Richard Ian, 10% owner
Acquired 5,484,320 American Depositary Shares (Open Market Sale) |
| 12 Aug 2026 | 424B5 |
| 12 Aug 2026 | 8-K: Entry into a Material Definitive Agreement; Other Events |
| 11 Aug 2026 | S-3MEF |
| 10 Aug 2026 | 424B5 |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 10 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 16 Jul 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
As reported in the Original Form 8-K, effective as of December 14, 2025 (the “Separation Date”), Craig Tooman agreed by mutual consent to end his employment with Silence Therapeutics plc (the “Company”). |
| 08 Jul 2026 | SCHEDULE 13D/A |
| 07 Jul 2026 |
Form 4: Griffiths Richard Ian, 10% owner
Acquired 330,072 American Depositary Shares (Open Market Sale) · Acquired 169,928 American Depositary Shares (Open Market Sale) · Acquired 129,180 American Depositary Shares (Open Market Sale) · 2 more |
| 23 Jun 2026 | 8-K: Regulation FD Disclosure |
| 16 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
Loading...
